Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,934.00-1.36%ETH$2,406.06-2.96%GOLD$4,384.50+1.19%OIL$103.82-1.90%
Smart Investors Daily
VI

NASDAQ · VIVS

VivoSim Labs, Inc.

Healthcare · Biotechnology

$0.27

Down-$0.01 (-3.06%)

Updated Sep 16, 2026, 11:32 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.82M
P/E ratio
-2.81
Dividend yield
0.00%
52-week range
$0.26 – $1.96
Volume
304.67K
Avg. volume
510.14K

Price performance

VIVS price history

1M range · 0 trading sessions · Daily adjusted prices

VIVS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest VIVS news

The latest Smart Investors Daily articles mentioning VIVS.

Stock researchCompany · Overview

VIVS research

Overview

Company profile and research snapshot.

Company profile

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humansSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liv

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By